Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 1-20 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 1 | ICEYE highstrong | Opp 9 Risk 3 | Thesis: Recent very large funding, high stated valuation, and evidence of expanding sovereign SAR demand support a durable multi-quarter scaling thesis. Why now: On June 9, 2026 ICEYE disclosed a €450 million primary Series F at valuation above €10 billion, with total round size above €1 billion including secondary, and later June context also referenced a €300 million revolving credit facility and additional sovereign satellite demand; those are recent business-state signals for a 1 year+ horizon. Evidence
Caveats: Some support is supporting article context rather than company-specific positive evidence. Several supporting demand/customer references are undated, so recency is uncertain for those claims. |
| 2 | SpaceX highstrong | Opp 9 Risk 4 | Thesis: SpaceX has the strongest evidence-set-backed long-horizon opportunity because it secured multiple large, recent government awards that deepen its role as a core military and civil space infrastructure provider, with contract scope spanning surveillance, communications backbone, and additional NASA crew missions. Why now: The timing is supported by late-May 2026 contract awards: a $2.29 billion Space Force data-network award dated May 26, 2026 and a $4.16 billion Space Force SB-AMTI award dated May 29, 2026/May 30, 2026, plus NASA's plan dated May 24, 2026 to add missions to SpaceX's commercial crew contract, all of which indicate durable backlog expansion and franchise entrenchment over a 1 year+ horizon. Evidence
Caveats: The reviewed sources' available source fields contain no direct positive or negative events for SpaceX; opportunity is inferred from high-materiality neutral facts and article summaries. Ticker mapping is noisy in the reviewed sources: SpaceX is shown with ticker TSLA, which should not be treated as validated public-company identity here. |
| 3 | Apex Space mediummedium | Opp 8 Risk 4 | Thesis: Apex has the strongest opportunity case in this screen because multiple dated June 2026 sources say it raised over $200 million at a $2.3 billion valuation specifically to scale high-rate satellite bus production for proliferated constellations, and a separate dated June 2026 article says Northrop partnered with Apex on space-based interceptors for Golden Dome. Together, these indicate fresh capital, scaling intent, and positioning with government/defense demand vectors over a 1 year+ horizon. Why now: Why now is strong because the key financing evidence is dated June 5, 2026 and the Northrop partnership article is dated June 1, 2026, making both recent within the 90-day recent evidence window and relevant to a 1 year+ scaling thesis. The June 5 financing event is later than the April 16 capacity/context article and therefore better reflects current business state. Evidence
Caveats: Most available evidence is neutral fact or supporting article context, not explicit positive events. Same-day repeated articles around the fundraise are not independent proof beyond corroboration. Some context sources are company-issued or article-level summaries, which are weaker than direct events. |
| 4 | AST SpaceMobile, Inc. highstrong | Opp 8 Risk 5 | Thesis: AST SpaceMobile has strong long-horizon opportunity because it achieved a critical regulatory milestone for a 248-satellite direct-to-device constellation and continues to show ecosystem buildout through operator partnerships and stated constellation scale targets. Why now: The key timing event is the FCC authorization dated April 21, 2026/April 22, 2026 granting authority for up to 248 satellites and direct-to-device service, a milestone that can unlock U.S. commercial and government use cases over a 1 year+ horizon. Later-dated company-site context on June 23, 2026 also says AST has nearly 60 operator partners and targets direct broadband to standard smartphones. Evidence
Caveats: Much of the evidence is company, press-release, or article-context based rather than independent hard performance metrics. The reviewed sources cites a target of 45 to 60 BlueBird satellites by end-2026 in article summary context, but this is not available as a direct structured fact here. |
| 5 | BlackSky Technology Inc. highstrong | Opp 8 Risk 4 | Thesis: BlackSky has the strongest recent opportunity evidence in the screen: a multi-year sole-source $99 million U.S. government IDIQ tied to next-generation Earth observation and space domain awareness development, plus a separate $25 million multi-year assured contract with a major international defense customer. Together these indicate current government demand, product validation, and longer-horizon backlog/ARR support. Why now: The why-now is supported by two dated recent wins inside the recent evidence window: on March 31, 2026 BlackSky said it received a multi-year sole-source $99 million U.S. government IDIQ and initial $2 million funding for advanced large-aperture payload design; on April 22, 2026 it announced a competitive $25 million multi-year assured contract with a major international defense customer and said it had four Gen-3 satellites on orbit and was rapidly deploying Gen-3 capacity while driving up backlog and annual recurring revenue. Evidence
Caveats: The $99 million figure is an IDIQ ceiling, not fully funded revenue at announcement; only an initial $2 million was specifically disclosed. Some corroboration repeats the same underlying announcement and should not be treated as independent evidence |
| 6 | Boeing highstrong | Opp 8 Risk 2 | Thesis: Boeing has the strongest opportunity evidence in this screen because the reviewed sources includes recent company-linked fact evidence that it won a $2 billion U.S. Space Force contract to build two next-generation MUOS communications satellites. The award covers design, development, production, testing, and on-orbit support for a critical military SATCOM network, with launches no earlier than 2031 and 2032 and constellation support through 2035. That is a material, durable space/defense win aligned with the 1 year+ horizon Why now: Why now is strong because the contract was reported on June 23-25, 2026, making it recent within the 90-day recent evidence window, and it represents a fresh, material U.S. defense-space award with multiyear strategic relevance Evidence
Caveats: Some corroborating rows are supporting article context and should not be overcounted as independent confirmation. Program financial benefits may phase in over a long cycle given first delivery timing in 2031. |
| 7 | Capella Space highstrong | Opp 8 Risk 4 | Thesis: Capella Space has the strongest opportunity profile in this screen because the reviewed sources includes a dated, company-specific contract fact showing it won a roughly $49 million SDA contract to build two satellites for a military communications demonstration, adding to evidence that it operates advanced SAR satellite capabilities and serves government and strategic customers. Why now: The April 8, 2026 SDA award is recent within the recent evidence window and is directly relevant to a 1 year+ horizon because it funds spacecraft design and development for a government demonstration program. Later context articles in April-June 2026 continue to depict Capella as an operating SAR platform with defense exposure. Evidence
Caveats: The positive contract evidence is classified as a neutral supporting fact in the reviewed sources, so direction is inferred from the business substance rather than explicit positive polarity labeling. Several contextual articles mention a planned acquisition or subsidiary status, but time-sensitive ownership/public-status interpretations should be treated cautiously because not all such references are direct, dated transaction-closing evidence. For example, and |
| 8 | Impulse Space mediummedium | Opp 8 Risk 4 | Thesis: Impulse Space has the strongest opportunity setup in this screen based on recent, company-linked financing evidence that it raised $500 million in Series D funding to scale production of orbital transfer vehicles, with article context also indicating expansion to support growing commercial and government demand. For a 1 year+ horizon, that capital base can support production scale-up and program execution. Why now: The catalyst is recent and dated: on June 2, 2026/June 3, 2026, Impulse Space disclosed a $500 million Series D and total capital raised above $1 billion, which is highly relevant for a 1 year+ scaling thesis. Evidence
Caveats: Some supportive items are supporting article context and should not be treated as independent confirmation if repeating the same financing announcement. Older commercial contract and government contract references in representative articles are outside the 90-day recent evidence window and therefore not primary recency support here. |
| 9 | Katalyst Space Technologies highstrong | Opp 8 Risk 6 | Thesis: Katalyst Space Technologies has a strong opportunity profile because the reviewed sources show recent evidence of both mission relevance and financing: a NASA Phase III SBIR contract to develop a rescue concept for the Neil Gehrels Swift Observatory and a later June 23, 2026 report that it raised $12 million to develop its NEXUS robotic spacecraft and expand satellite servicing. Why now: Why now is strong because the latest dated evidence on June 23, 2026 adds new capital after the May 29, 2026 NASA-related mission context, supporting a 1 year+ thesis that the company is moving from concept credibility toward funded development in on-orbit servicing. Evidence
Caveats: Part of the positive case comes from company-issued materials and supporting article context rather than independent positive evidence. The May 29, 2026 article includes a dated source date but describes an announcement text beginning 'August 11, 2025'; chronology should therefore be read carefully, with the treated as the recency marker for this retrieved item. Citation |
| 10 | Northrop Grumman Corp mediumstrong | Opp 8 Risk 3 | Thesis: Northrop Grumman has the strongest reviewed sources-supported opportunity profile in this screen due to multiple recent space-defense catalysts: inclusion in the April 8, 2026 Andromeda RG-XX awards, a June 1, 2026 partnership with Apex on Golden Dome space-based interceptors, and a June 22, 2026 $398M Space Force contract for the Enhanced Protected Tactical SATCOM Prototype. Together these support a durable 1 year+ defense-space demand thesis. Why now: The setup is current and cumulative: April 8, 2026 Andromeda participation, June 1, 2026 Golden Dome interceptor partnership, and June 22, 2026 award of a $398M protected satcom contract all fall within the 90-day recent evidence window and point to sustained momentum. Evidence
Caveats: The reviewed sources does not provide direct business impact breakdowns beyond the $398M contract article. Some support is supporting article context rather than dated events. |
| 11 | Observable Space mediummedium | Opp 8 Risk 4 | Thesis: Observable Space has the strongest positive setup in this screen because the reviewed sources contain dated evidence that it raised a $90 million Series A and secured a $94 million U.S. Space Force optical-systems contract, supporting capital availability, customer validation, and potential multi-quarter execution runway. Why now: The timing is favorable because on May 28, 2026 the company was reported to have both closed a $90 million Series A and announced a $94 million U.S. Space Force award, with additional follow-on reporting on June 9, 2026 indicating the contract landed just weeks after the raise, suggesting a recent step-change in funding and government traction for a 1 year+ horizon Evidence
Caveats: Positive direction is inferred from neutral facts plus article summaries; the reviewed sources does not provide explicit positive events. Same-article repeated rows are not independent confirmation. Supporting web-search evidence is context and should be treated below directly cited company evidence. |
| 12 | PLD Space highstrong | Opp 8 Risk 4 | Thesis: PLD Space has recent financing, strategic customer/investor validation, infrastructure investment, and a first commercial launch contract, all of which support a durable launch-scaling thesis over the next year-plus. Why now: The reviewed sources show a sequence of material developments: €180 million Series C on March 4, 2026, €30 million EIB venture debt signed April 7, 2026 and reported May 6, 2026/04-07, first commercial contract reported May 21, 2026, and €35 million Kourou launch-complex investment on June 1, 2026 while MIURA 5 remained on track for a late-2026 first test flight. That is strong state-change evidence for a 1 year+ horizon. Evidence
Caveats: Risk evidence is partly inferred from dependency on future launch milestones rather than a disclosed adverse event. Most support is supporting article context, though the chronology is consistent and material. |
| 13 | Quantum Space mediummedium | Opp 8 Risk 5 | Thesis: Quantum Space has the clearest evidence-backed opportunity profile in this screen: within the recent evidence window it announced a SPAC merger expected to bring substantial capital and public-market access, and later won a Pentagon-funded orbital refueling spacecraft contract built on its Ranger platform. Those developments support a durable 1 year+ thesis around funding access, national-security positioning, and product relevance in on-orbit logistics. Why now: The evidence is recent and sequenced: on June 8, 2026 Quantum Space announced its planned SPAC merger and expected Nasdaq listing under QSPC Evidence
Caveats: Most available evidence is external overlay context rather than first-party positive or negative events. Same-theme repetition across June articles is not independent confirmation. Ticker QSPC is prospective after the expected SPAC close per June 8, 2026 evidence, not confirmed as already trading under that symbol |
| 14 | True Anomaly highstrong | Opp 8 Risk 4 | Thesis: True Anomaly has the strongest opportunity profile in this screen because the reviewed sources contain dated, company-linked evidence that it raised $650 million in Series D financing at a $2.2 billion valuation on April 28, 2026 and was selected by the U.S. Space Force for the Space-Based Interceptor program on May 4, 2026. For a 1 year+ horizon, that combination of fresh capital plus program participation supports scaling, product development, and defense-space positioning. Why now: The recent sequence matters: on April 28, 2026, True Anomaly announced a $650 million Series D at a $2.2 billion valuation, also. Then on May 4, 2026, a dated article said the company was selected by the U.S. Space Force Space Systems Command for the Space-Based Interceptor program. That capital-plus-program sequence is directly relevant to a long-horizon growth thesis. Evidence
Caveats: Most evidence is external overlay context/facts rather than primary data source direct events. Several sources repeat the same April 28 financing story and are not independent confirmation of different events. The company-site article is undated, so recency-sensitive claims from it should be treated cautiously. |
| 15 | Anduril Industries mediummedium | Opp 7 Risk 5 | Thesis: Anduril has a credible 1 year+ opportunity setup from recent participation in major U.S. defense-space programs and fresh financing context. Recent article context says Anduril was among companies awarded Space Force Andromeda contracts for the RG-XX satellite effort on April 8, 2026, and a later article says Anduril raised a $5B Series H round published June 19, 2026, supporting capital availability for scaling in defense-space programs. Why now: The timing is supported by recent 2026 article context around Space Force Andromeda participation and the June 19, 2026 financing context, which together suggest active momentum over the last quarter. Evidence
Caveats: Most evidence is weak context-only article evidence, not direct positive events in the available ranking rows. |
| 16 | Astroscale mediummedium | Opp 7 Risk 4 | Thesis: Astroscale has the clearest 1 year+ opportunity setup in this screen: within the recent evidence window article context shows recent funding support, strategic growth financing for medium-to-long-term expansion, and a shift from demos toward repeatable commercial missions, including defense-related servicing and a 2027 inspection mission pipeline. Why now: Recency is the main reason: on June 22, 2026 SpaceNews said Astroscale was 'working to transition from technology demonstrations to a regular series of missions, bolstered by a recent capital infusion' and saw 'repeatable business opportunities' particularly among defense customers. On May 19, 2026 financing materials said the company would raise 30.6 billion yen to secure medium-to-long-term growth funding 'in anticipation of transitioning to a phase of continuous order acquisition'. On April 6, 2026 Astroscale revealed its ISSA-J1 mission scheduled for launch in 2027. Evidence
Caveats: Most within the recent evidence window evidence is supporting article context, not structured company-specific events; reviewed sources warns supporting article context is weaker than direct event/fact evidence. Same-article repeated weak-context rows are not independent confirmation. Older 2023 and 2025 articles exist in representative articles but fall outside the 90-day recent evidence window for ranking use. |
| 17 | ClearSpace mediummedium | Opp 7 Risk 3 | Thesis: Best opportunity profile in this screen based on multiple dated article-context items showing the company remains active in in-orbit servicing/debris removal, has financing support, is ramping toward ClearSpace-1, and is expanding into defense-adjacent partnership activity. For a 1 year+ horizon, that combination supports a credible strategic growth and market-positioning thesis. Why now: Why now is supported by recent dated context: on June 24, 2026, SpaceNews reported ClearSpace signed an MOU with Shield Space to develop sovereign space defense capabilities for the UK and allies, indicating adjacent market expansion. On May 19, 2026, the company site said it had finalized a EUR 26.7 million Series A and was ramping operations ahead of ClearSpace-1 scheduled to launch in 2026. These dated items fit a 1 year+ horizon because they point to ongoing commercialization and mission preparation. Evidence
Caveats: Most evidence is supporting article context, not direct positive events. The financing article published on May 19, 2026 references January 19, 2023 for the Series A round, so funding recency versus page recency should not be conflated. |
| 18 | Cowboy Space mediummedium | Opp 7 Risk 4 | Thesis: Cowboy Space has the strongest positive evidence in this screen: a large Series B financing at a substantial valuation, explicit plans to build vertically integrated rockets plus orbital data-center infrastructure, and stated hiring/buildout activity. That combination supports a durable 1 year+ strategic opportunity thesis. Why now: Multiple dated articles on May 11, 2026 report Cowboy Space raised $275 million in Series B financing at a $2 billion valuation to build rockets with orbital data-center upper stages, and a TechCrunch article says the company is standing up its own rocket program with a first launch expected before end-2028 Evidence
Caveats: The reviewed sources contain no explicit negative event evidence; risk is inferred from execution complexity and long timeline, not from adverse events. Several supporting rows repeat the same May 11, 2026 financing story and are not independent confirmation. Some supporting article context is undated and should be treated cautiously for recency. |
| 19 | Dawn Aerospace mediummedium | Opp 7 Risk 3 | Thesis: Dawn Aerospace has the strongest opportunity evidence in this screen because a recent dated company article says it closed a $25 million Series B at a $195 million post-money valuation to accelerate global expansion of reusable space transportation. The funding is directly tied to rollout, commercial scaling in the US and Europe, and support for an expanding international customer base, which fits a 1 year+ horizon. Why now: The key catalyst is recent and explicit: on June 16, 2026 the company announced the Series B close and said the proceeds will finance global rollout and scaling of commercial and operational teams in the US and Europe. Evidence
Caveats: Evidence comes from a company-published article, so it is not fully independent. No direct structured positive event row is provided beyond supporting article context. |
| 20 | Eutelsat Communications SA mediummedium | Opp 7 Risk 4 | Thesis: Eutelsat has a strong long-horizon opportunity case from the reviewed sources' membership rationale stating it is supervising a 264-satellite IRIS2 element and won a €350M French defense satellite contract with sovereign LEO capacity. That combines infrastructure scale with government-backed demand. Why now: The reviewed sources' membership rationale cites current program/contract relevance through support articles 2026-04, and: but were not provided in the payload, limiting precise timing narration. Evidence
Caveats: The reviewed sources does not provide for the membership-support article IDs. Opportunity score is tempered by the absence of kept direct evidence in the ranking payload. |
Risk view
Showing rows 341-360 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 341 | Nanoracks lowweak | Opp 2 Risk 1 | Thesis: No retained adverse evidence is provided. The main risk is evidentiary staleness rather than a documented business problem. Why now: There is no valid within the recent evidence window catalyst. The only company-specific article is at with September 2, 2025, and the reviewed sources say it was excluded by the 90-day cutoff. Evidence
Caveats: The only cited article is outside the selected 90-day evidence recent evidence window and therefore should not drive strong ranking. This is supporting source context, not merged serving evidence. No retained direct positive or negative evidence remain after recent evidence window. |
| 342 | NeevCloud lowweak | Opp 1 Risk 1 | Thesis: No material adverse thesis is supportable because no direct negative evidence survived the 90-day recent evidence window in the retained reviewed sources. Why now: Why now is weak: despite membership rationale referring to partnerships and orbital data center / AI inferencing context, the retained reviewed sources contain zero evidence after recent evidence window and no citable article summaries. Caveats: Phase-2 membership rationale references, and: but no summaries or direct evidence are retained here for factual claims. The reviewed sources itself says NeevCloud is space-adjacent and not clearly a qualifying space company. |
| 343 | NewOrbit lowweak | Opp 1 Risk 1 | Thesis: No material adverse evidence is available in the reviewed sources. Why now: No retained post-recent evidence window evidence are available, so current timing cannot be established from these reviewed sources. Caveats: Only membership rationale supports the company in this screen. No citeable retained evidence after recent evidence window. |
| 344 | OHB SE lowweak | Opp 1 Risk 1 | Thesis: No within the recent evidence window direct negative evidence was available, so there is insufficient reviewed sources support to form a material adverse thesis. Why now: There is no retained article or evidence row after the 90-day recent evidence window for OHB SE; recency-based ranking is therefore not supported by the reviewed sources. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Phase-2 cohort membership rationale is not directional evidence and cannot substitute for retained article evidence. Because no article were retained after recent evidence window, no company-specific factual thesis can be cited from these reviewed sources. |
| 345 | Optimized Electrotech Pvt Ltd lowweak | Opp 1 Risk 1 | Thesis: No retained within the recent evidence window direct negative evidence was available, so a material risk thesis is not supported. Why now: No retained company evidence after the 90-day recent evidence window means there is no evidence-set-backed timing reason to rank this name higher now. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale cites article IDs, and, but no or retained evidence text are available here. Without retained article evidence, absence of bad news is not positive evidence. |
| 346 | OrbitOn lowweak | Opp 1 Risk 1 | Thesis: No direct negative evidence is present, but because the only cited evidence is an older database-style listing that falls outside the recent evidence window, current execution and business-state risk cannot be assessed confidently. Why now: Why now is weak because the only visible article has March 4, 2025 on a source date basis and the reviewed sources report no current evidence was retained after the March 29, 2026 cutoff Evidence
Caveats: Only article detail shown is outside the 90-day recent evidence window and was dropped. Database/listing style evidence is weaker than company-specific event evidence. External supporting source context is relevance context, not stronger than direct retained evidence. |
| 347 | Paras Defence and Space Technologies Ltd lowweak | Opp 1 Risk 1 | Thesis: No material adverse thesis is supported within the reviewed sources' 90-day evidence window. Risk is low-scored because evidence is absent, not because business risk is disproven. Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Paras Defence and Space Technologies Ltd. Caveats: Phase-2 membership rationale references article, but the reviewed sources does not provide or quoted evidence for that item, so it cannot be used as a factual directional citation. No direct positive or negative evidence survived the 90-day recent evidence window. |
| 348 | Parsons Corporation lowweak | Opp 1 Risk 1 | Thesis: No material adverse evidence is available within the reviewed sources' recent evidence window. Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Parsons Corporation. Caveats: Phase-2 membership rationale references articles: and, but the reviewed sources provide no for citation. Article-level market-report inclusion is weaker than direct company-specific operating evidence. |
| 349 | PhysicsX lowweak | Opp 1 Risk 1 | Thesis: No direct negative evidence is retained, so there is no supported material risk thesis either. Why now: There is no current catalyst evidence because articles after recent evidence window = 0 and evidence after recent evidence window = 0. Caveats: Funding-round context in rationale lacks -cited retained evidence here. Space relevance is explicitly weak in the reviewed sources rationale. |
| 350 | PierSight lowweak | Opp 1 Risk 1 | Thesis: No material adverse evidence is supplied after recent evidence filtering, so a risk thesis is also not supported. Why now: Why now is unsupported because the reviewed sources show no surviving evidence after recent evidence filtering; there is no direct dated milestone or problem signal to anchor a 1 year+ thesis. Caveats: Only membership-level rationale is present; no citable evidence survived. No direct company-specific positive or negative events are available in the reviewed sources. Low scores reflect evidence scarcity. |
| 351 | Pilot Photonics lowweak | Opp 2 Risk 1 | Thesis: No material adverse evidence is available; the main risk is that the reviewed sources lack retained direct evidence on timing, follow-on awards, or commercial conversion beyond the cited membership rationale. Why now: Why now is limited because only membership rationale references article: and the reviewed sources provide no or retained evidence after recent evidence window. Caveats: The ESA contract claim cannot be elevated strongly without the underlying article or summary in the reviewed sources. Coverage data shows evidence after recent evidence window 0. Opportunity may be real, but reviewed sources support is too sparse for higher conviction. |
| 352 | Pixxel lowweak | Opp 2 Risk 1 | Thesis: The reviewed sources contain no retained adverse evidence within the recent evidence window, so there is no evidence-based risk thesis beyond execution uncertainty from being a private space startup with limited current reviewed sources support. Why now: Why now is weak because the only cited article summary in the reviewed sources are outside the 90-day evidence window, October 13, 2025 Caveats: The representative article for Pixxel is outside the recent evidence window and evidence recent evidence review shows kept_rows 0. No retained structured positive or negative rows are available. |
| 353 | Pixxel lowweak | Opp 1 Risk 1 | Thesis: No material adverse evidence is retained, so there is no evidence-based negative thesis in these reviewed sources version. Why now: Why now is weak because no articles or evidence were retained after the March 29, 2026 cutoff in these reviewed sources version. Caveats: Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Membership rationale references article IDs without, which cannot be cited as factual support here. |
| 354 | Portal Space Systems lowweak | Opp 1 Risk 1 | Thesis: No retained within the recent evidence window negative evidence was available, so the reviewed sources does not support a material risk view. Why now: There is no retained evidence inside the 90-day recent evidence window, so no current catalyst or business-state update is citable from these reviewed sources. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale references article IDs, and, but no or retained summaries are supplied. Low score reflects lack of citable evidence, not a negative business judgment. |
| 355 | Precursor SPC lowweak | Opp 1 Risk 1 | Thesis: No material negative thesis is supportable from retained evidence in these reviewed sources. Why now: Why now is weak because the reviewed sources show no available post-recent evidence window evidence; evidence recent evidence review kept_rows is 0 and coverage data articles after recent evidence window is 0. Caveats: Phase-2 rationale references without or retained evidence detail, so it is not sufficient for factual grounding here. No direct positive or negative evidence arrays are populated. Low scores are an evidence-gap judgment, not a business conclusion. |
| 356 | Quantum Opus lowweak | Opp 1 Risk 1 | Thesis: No material adverse thesis is supported because the reviewed sources contain no direct negative evidence within the recent evidence window. Why now: There is no clear why-now catalyst because coverage after the 90-day recent evidence window is empty. Caveats: Membership support exists but no representative article is provided for. No retained evidence after recent evidence window. No direct business-state update, financing, contract, or customer traction evidence is available. |
| 357 | Quantum Systems GmbH lowweak | Opp 1 Risk 1 | Thesis: No direct negative evidence is available. The reviewed sources does not provide material adverse company-specific facts within the recent evidence window. Why now: There is no supported near-term or long-horizon catalyst in the reviewed sources because zero post-recent evidence window evidence were available. Caveats: Phase2 rationale references article IDs: and: as article context only, but no were provided in the reviewed sources. Coverage data shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Context-only mentions and portfolio references cannot substitute for direct positive or negative evidence. |
| 358 | Rogers Communications Inc. lowweak | Opp 1 Risk 1 | Thesis: No material adverse thesis is supported by the reviewed sources. Risk is scored low only because evidence is absent, not because the company is de-risked. Why now: There is no available 90-day evidence for Rogers in these reviewed sources; coverage data shows zero article ids after recent evidence window and zero evidence after recent evidence window, so there is no supported 'why now' catalyst in the provided evidence. Caveats: No direct positive or negative evidence were available after the 90-day recent evidence window for Rogers. Phase2 rationale references support references including: but no article or article summary for that item is included in these reviewed sources, so it cannot be cited as factual evidence. Opportunity score is kept near zero because the evidence standard require positive evidence, not mere absence of risk. |
| 359 | Rogue Space Systems lowweak | Opp 2 Risk 1 | Thesis: No material negative development is documented in the retained reviewed sources; the principal risk is low evidence quality and lack of dated corroboration. Why now: The only retained evidence is an undated external sector page listing Rogue Space Systems as an operating in-orbit servicing company, so the why-now is weak and recency is uncertain. Evidence
Caveats: Evidence is undated and explicitly not recency proof per reviewed sources policy. Same-article repeated rows are not independent confirmation. No direct evidence of contracts, funding, milestones, or setbacks is included. |
| 360 | Romanian InSpace Engineering lowweak | Opp 1 Risk 1 | Thesis: No material adverse evidence is available, so no supported risk thesis exists beyond sparse-coverage uncertainty. Why now: No why-now catalyst is evidenced because there are no retained 90-day evidence. Caveats: Reviewed evidence references but provides no. Single historical membership-support mention only. No retained evidence after recent evidence window. |